Nazione: Germania
Lingua: inglese
Fonte: HMA (Heads of Medicines Agencies)
feline calicivirus 4.6 pfu, Feline Panleucopaenia (Infectious Enteritis) Virus 4.3 TCID50, Feline Rhinotracheitis (herpes) Virus 5.2 pfu
Intervet Intenational BV
QI06AD04
Suspension for injection
Feline panleucopenia virus / parvovirus vaccine + Feline rhinotracheitis virus vaccine + Feline calicivirus vaccine
Cats Non Food
2011-06-17
Nobivac Tricat Trio Renewal (DE/V/0240/001R/001) SUMMARY OF PRODUCT CHARACTERISTICS Nobivac Tricat Trio Renewal (DE/V/0240/001R/001) 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Tricat Trio, lyophilisate and solvent for suspension for injection, for cats (AT, DE: Nobivac RCP; ES: Nobivac Tricat Novum, SE: Nobivac Tricat Novum* vet) * The affix ‘Novum’ is added temporarily during transitional period between old and new product. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Per dose of 1 ml: Lyophilisate ACTIVE SUBSTANCES: live attenuated feline calicivirus, strain F9: 4.6 log 10 PFU 1 ; live attenuated feline herpes virus type 1, strain G2620A: 5.2 log 10 PFU 1 ; live attenuated feline panleucopenia virus, strain MW-1: 4.3 log 10 CCID 50 2 1 PFU: Plaque-Forming Units 2 CCID 50: Cell Culture Infective Dose 50% EXCIPIENTS: For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Off-white lyophilisate 4. CLINICAL PARTICULARS 4.1. TARGET SPECIES Cats 4.2. INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of cats: − to reduce the clinical signs caused by infection with feline calicivirus (FCV) and feline herpes virus type 1 (FHV), − to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPLV). Onset of immunity: for FCV and FHV: 4 weeks; for FPLV: 3 weeks. Duration of immunity for FCV and FHV: 1 year, for FPLV: 3 years. 4.3. CONTRAINDICATIONS See point 4.7 4.4. SPECIAL WARNINGS Leggi il documento completo